Skip to content
request demo
Trusted by 100+ leading biopharma companies

From 33,575 Drugs to 5 Acquirable Targets. In a Single Agentic Workflow Run.

Ferma's pharma asset screening workflow encodes your portfolio fit criteria, clinical differentiation standards, and deal feasibility thresholds -- and runs the entire BD evaluation automatically, producing a committee-ready package with every output cited.

request demo

One Pharma Asset Screening Run. A Complete BD Diligence Package.

scorecard
Composite Scorecard
Clinical differentiation, IP strength, deal feasibility, and competitive positioning - scored across pharma BD dimensions and ranked. Every score traced to source data.
rNPV Valuation Model
rNPV Valuation Model
Bottom-up risk-adjusted NPV using epidemiology, clinical PoS by phase, pricing benchmarks, and competitive dynamics - the standard rNPV valuation model for pharma BD licensing decisions. Stress-tested across bear, base, and bull scenarios. Adjustable inputs.
Com Lands
Competitive Drug Landscape
All drugs in the TA - efficacy, safety, deal activity, and regulatory status - scored, ranked, and contextualized against the pharma asset being screened.
Deal Comparables Analysis
Deal Comparables Workbook
Structured pharma deal comparables by TA, mechanism, and phase - upfront, milestones, royalties, and total deal value. Excel format, ready for the IC deck.
catalyst
Catalyst Timeline
Upcoming readouts, FDA actions, PDUFA dates, and milestone triggers for the screened pharma asset and its full competitive set.
data exports
Executive Summary Brief
2-page PDF executive summary with scorecard, investment thesis, key risks, and recommended next steps - formatted for pharma BD licensing committee review.

How Ferma's Pharma Asset Screening Workflow Works

S T E P  1

Define Your Criteria

Portfolio fit parameters, clinical differentiation thresholds, deal structure preferences, and indication focus. Your pharma BD methodology, encoded as the asset screening workflow plan.

S T E P  2

Execution Workflow

Ferma's Agentic Workflow pulls from 23,000+ clinical and commercial drugs, 35,000+ clinical trials, and 2,000+ deal transactions - applying your encoded screening criteria across a 7-stage funnel to surface only the assets that meet your portfolio fit and clinical differentiation thresholds.

S T E P  3

Receive Your Package

Ranked pharma asset shortlist with composite scorecards, rNPV models, deal comps, and exec summaries for each qualifying BD target. Every claim cited. Exportable to PowerPoint, Excel, or PDF.

23
K
clinical/commercial drugs
35
K
Clinical Trials
2
K
Deals Dataset
quote

I ran a screen on a new indication in under a day. The output had the composite scorecard, the deal comps, the rNPV inputs — everything I needed to take it to the next IC conversation.

Senior Manager
Corporate Development, Specialty Biopharma
CTA Home

Your next acquisition target is already in the pipeline. Ferma finds it first.

Request Demo

Frequently Asked Questions

How is Ferma's Opportunity Screener different from running a search in Cortellis or Evaluate Pharma?

Cortellis and EvaluatePharma return a list of assets matching your search criteria, your pharma BD team then manually pulls clinical data, models the financials, sources deal comps, and formats the IC package from scratch. Ferma's pharma asset screening workflow runs the entire process automatically: composite scoring, rNPV modeling, deal comps, and executive summary formatting in a single run. What takes a Cortellis-based workflow days to assemble, Ferma delivers as a finished BD diligence package.

How do pharma BD teams build a composite scorecard for asset evaluation?

A composite scorecard for pharma BD asset evaluation scores each asset across multiple dimensions -- clinical differentiation, IP strength, deal feasibility, competitive positioning, and strategic fit - weighting each factor against your portfolio criteria. Traditionally this requires pulling data from multiple sources and building the scoring model manually. Ferma's Opportunity Screener Agentic Workflow encodes your scoring criteria as the workflow plan and generates the composite scorecard automatically, with every score traced back to the source data. The output is a ranked shortlist your team can take directly into an IC conversation.

How long does pharma asset screening take with AI?

With Ferma's pharma asset screening workflow, a full screen - from 33,575 drugs to a ranked shortlist with composite scorecards, rNPV models, deal comps, and an executive summary - runs in under a day. A senior BD manager at a specialty biopharma company ran a new indication screen in under a day and had everything needed for the next IC conversation. Traditional manual screening across Cortellis, financial modeling tools, and deal databases typically takes days to weeks to reach the same output.